Matt McNamara - AVITA Therapeutics Director
Director
Mr. Matt McNamara was appointed as NonExecutive Director of Avita Medical Ltd. effective 22 October 2012. Mr McNamara is currently the Chief Investment Officer and Fund Manager of Octa Phillip Bioscience Managers. Matt has over 23 years experience in the healthcare medical sciences sector. After initially being a molecular biology research assistant Matt spent 11 years in Sales Marketing and General Management with Merck Co. and Johnson Johnson Medical Pty. Ltd. respectively. He has served as SVP Business Development for a University of Sydney spin out eBioinformatics Inc. and was CEO of a Life Sciences VC fund SciCapital Pty. Ltd. since 2012.
| Tenure | 12 years |
| Phone | 61 8 6168 8400 |
| Web | http://www.carnegiece.com |
AVITA Therapeutics Management Efficiency
The company has return on total asset (ROA) of (8.19) % which means that it has lost $8.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (27.05) %, meaning that it generated substantial loss on money invested by shareholders. AVITA Therapeutics' management efficiency ratios could be used to measure how well AVITA Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 99.29 K in total debt with debt to equity ratio (D/E) of 0.16, which may suggest the company is not taking enough advantage from borrowing. AVITA Therapeutics has a current ratio of 8.22, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist AVITA Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, AVITA Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AVITA Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AVITA to invest in growth at high rates of return. When we think about AVITA Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Daniel Arrigoni | MGIC Investment Corp | 70 | |
| Gary Poliner | MGIC Investment Corp | 67 | |
| John Fazzini | Visionary Education Technology | 75 | |
| Jeffrey Flug | PennantPark Investment | 58 | |
| Kenneth Jastrow | MGIC Investment Corp | 72 | |
| Harvey Eads | Visionary Education Technology | 73 | |
| Sheryl Sculley | MGIC Investment Corp | 68 | |
| Adam Bernstein | PennantPark Investment | 57 | |
| Jodeen Kozlak | MGIC Investment Corp | 57 | |
| Melissa Lora | MGIC Investment Corp | 58 | |
| Donald Nicolaisen | MGIC Investment Corp | 70 | |
| April Lee | PennantPark Investment | N/A | |
| Chuck Chaplin | MGIC Investment Corp | 63 | |
| Samuel Katz | PennantPark Investment | 55 | |
| Timothy Holt | MGIC Investment Corp | 67 | |
| Stephen Appel | Visionary Education Technology | 64 | |
| Michael Lehman | MGIC Investment Corp | 70 | |
| Danforth Leitner | Visionary Education Technology | 78 | |
| Analisa Allen | MGIC Investment Corp | 61 | |
| Cassandra Carr | MGIC Investment Corp | 73 | |
| Mark Zandi | MGIC Investment Corp | 61 | |
Management Performance
| Return On Equity | -27.05 | |||
| Return On Asset | -8.19 |
AVITA Therapeutics Leadership Team
Elected by the shareholders, the AVITA Therapeutics' board of directors comprises two types of representatives: AVITA Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AVITA. The board's role is to monitor AVITA Therapeutics' management team and ensure that shareholders' interests are well served. AVITA Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AVITA Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Licciardo, Joint Company Secretary | ||
| Jeremy Cook, Director | ||
| Fiona Wood, Non-Executive Director | ||
| William Marshall, VP of Operations and Quality | ||
| Donna Shiroma, General Counsel | ||
| Michael Perry, Director | ||
| Gabriel Chiappini, Company Secretary | ||
| Andrew Quick, VP of Research and Technology | ||
| Tim Rooney, Interim CEO | ||
| Debbie Garner, Vice President of Global Marketing | ||
| Troy Barring, COO | ||
| Damien McDonald, Non-Executive Director | ||
| Lou Panaccio, Chairman of the Board | ||
| Stella Sung, IR Officer | ||
| Ross Saunders, Vice President - Sales and Marketing | ||
| Dale Sander, CFO | ||
| Kate Goland, Joint Company Secretary | ||
| Louis Drapeau, Non-Executive Director | ||
| Lorraine Glover, General Manager of Asia Pacific | ||
| Terry Bromley, Vice President - Commercial Operations | ||
| Katie Bush, Vice President Medical Affairs | ||
| Matt McNamara, Director | ||
| Suzanne Crowe, Non-Executive Director | ||
| Ian Macpherson, Non-Executive Deputy Chairman of the Board | ||
| Adam Kelliher, CEO |
AVITA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AVITA Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -27.05 | |||
| Return On Asset | -8.19 | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 21.33 M | |||
| Shares Owned By Insiders | 6.97 % | |||
| Shares Owned By Institutions | 38.59 % | |||
| Price To Earning | (3.57) X | |||
| Price To Book | 50.00 X | |||
| Price To Sales | 126.94 X | |||
| Revenue | 1.22 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AVITA Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AVITA Therapeutics' short interest history, or implied volatility extrapolated from AVITA Therapeutics options trading.
Pair Trading with AVITA Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AVITA Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AVITA Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in AVITA Pink Sheet
If you are still planning to invest in AVITA Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AVITA Therapeutics' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance |